JCEM:他汀类药物使用与性激素的关系

2019-06-04 xing.T 网络

由此可见,他汀类药物使用者的SHBG和DHEA水平降低。鉴于他汀类药物治疗的使用日益增加,这一相关性值得引起关注。

根据2018年美国心脏病学会/美国心脏协会胆固醇指南,适合接受他汀类药物治疗以减少动脉粥样硬化血管疾病风险的人数大大增加。他汀类药物抑制胆固醇生物合成,这可能会损害性腺类固醇的合成。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员旨在大型流行病学研究中评估他汀类药物对内源性激素的影响。

在基线评估中有6814名MESA参与者。其中,6171名参与者测量了血清性激素水平:脱氢表雄酮(DHEA)、性激素结合球蛋白(SHBG)、雌二醇(E2)、总生物可利用睾酮(T)。多变量线性回归模型用于评估他汀类药物与每种性激素之间的关系。 

该研究纳入的他汀类药物使用者中有345名女性(17.4%)和464名男性(14.7%),平均年龄为67岁,41%为白人,29%为黑人,11%为中国人,19%为西班牙裔人。他汀类药物使用者与非他汀类药物使用者相比,女性平均SHBG低3.54nmol/L(p<0.01),男性低3.37nmol/L(p<0.001); 在调整潜在的混杂因素后,女性的DHEA值为1.06nmol/L(p<0.05),男性为0.70 nmol/L(p<0.01)。随着进一步倾向得分的调整,他汀类药物使用者与非使用者相比,平均DHEA和SHBG水平分别为0.67nmol/L(p<0.05)和3.49nmol/L(p<0.001)。E2、总T、生物可利用T与他汀类药物使用之间未发现显著相关性。

由此可见,他汀类药物使用者的SHBG和DHEA水平降低。鉴于他汀类药物治疗的使用日益增加,这一相关性值得引起关注。 

原始出处:

Oludamilola W Oluleye,et al.Association between statin use and sex hormone in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort.J Clin Endocrinol Metab. 2019.https://doi.org/10.1210/jc.2019-00530

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-07-21 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-12-18 smallant2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2044554, encodeId=33782044554f2, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat May 02 17:54:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063248, encodeId=7c2d206324867, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Jul 21 13:54:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777866, encodeId=27341e7786619, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Dec 18 08:54:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971582, encodeId=443b19e15828f, content=<a href='/topic/show?id=797b8e67141' target=_blank style='color:#2F92EE;'>#药物使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87671, encryptionId=797b8e67141, topicName=药物使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f67438, createdName=xiaogang317, createdTime=Sun Apr 12 04:54:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286393, encodeId=4e7e12863939c, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Jun 06 11:54:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367282, encodeId=b7cc36e28274, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Jun 04 20:56:08 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-06-04 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Neurology:他汀类药物不会增加多发性神经病的风险

由此可见,使用他汀类药物不会增加慢性多发性神经病的风险。因此,他汀类药物不应常规地从多发性神经病患者的药物选择中去除。

GUT:他汀类药物与结肠镜后结肠直肠癌

研究认为,他汀类药物可降低结肠镜后结肠直肠癌风险,特别是近端癌

JAHA:终末期肾病前他汀类药物治疗与之后结局的关系

由此可见,在非透析依赖性慢性肾病的退伍军人中,转变为终末期肾病之前的1年内使用他汀类药物治疗与有利的早期终末期肾病结局相关。

JAHA:经导管主动脉瓣膜置换术后他汀类药物使用与死亡率的关系

由此可见,在TAVR患者的观察性倾向性匹配分析中,与未使用他汀类药物相比,他汀类药物使用与心血管和非心血管死亡率降低相关。鉴于他汀类药物明显保护作用的早期出现,尽管存在倾向匹配方法,但这种结果可能由多效性或残余混杂因素所致。

Neurology:自发性脑出血患者他汀类药物与出血性水肿

由此可见,入院前使用他汀类药物治疗ICH与入院时rPHE降低无关。在未来的研究中,需要控制相对于ICH发作的影像学检查时间,以免受到混淆。